BiotechTube

FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer, Liver Metastases, Chemotherapy

Trial Timeline

Apr 1, 2004 → Aug 1, 2007

NCT ID
NCT00208260

About FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX

FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX is a phase 2/3 stage product being developed by Chugai Pharmaceutical for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00208260. Target conditions include Colorectal Cancer, Liver Metastases, Chemotherapy.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00208260Phase 2/3Completed

Competing Products

20 competing products in Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
ALIMTA + OxaliplatinEli LillyPhase 2
52
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
41
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
65
CPT-11 based regimensDaiichi SankyoPre-clinical
23
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
52
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
41
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + irinotecanDaiichi SankyoPhase 2
52
CS-7017 + PlaceboDaiichi SankyoPhase 2
52
Patritumab DeruxtecanDaiichi SankyoPhase 2
52
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
33
DS-8273a + nivolumabDaiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 2
52

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77